Tower Research Capital LLC TRC Acquires 4,809 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Tower Research Capital LLC TRC increased its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 302.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 6,399 shares of the company’s stock after purchasing an additional 4,809 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Voyager Therapeutics were worth $54,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. SummerHaven Investment Management LLC lifted its stake in shares of Voyager Therapeutics by 1.9% during the 4th quarter. SummerHaven Investment Management LLC now owns 74,146 shares of the company’s stock worth $626,000 after purchasing an additional 1,367 shares during the last quarter. Bank of New York Mellon Corp increased its position in Voyager Therapeutics by 0.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 192,869 shares of the company’s stock valued at $1,495,000 after buying an additional 1,455 shares in the last quarter. Ritholtz Wealth Management increased its position in Voyager Therapeutics by 11.8% during the 4th quarter. Ritholtz Wealth Management now owns 19,759 shares of the company’s stock valued at $167,000 after buying an additional 2,089 shares in the last quarter. Gladius Capital Management LP acquired a new position in Voyager Therapeutics during the 3rd quarter valued at about $25,000. Finally, Silverarc Capital Management LLC increased its position in Voyager Therapeutics by 4.0% during the 3rd quarter. Silverarc Capital Management LLC now owns 103,966 shares of the company’s stock valued at $806,000 after buying an additional 3,966 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Stock Performance

VYGR traded up $0.05 during trading on Tuesday, hitting $7.82. The stock had a trading volume of 495,064 shares, compared to its average volume of 888,730. The firm has a market capitalization of $425.33 million, a P/E ratio of 2.53 and a beta of 0.96. The company’s 50-day moving average price is $8.81 and its 200 day moving average price is $7.97. Voyager Therapeutics, Inc. has a twelve month low of $6.06 and a twelve month high of $14.34.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Wednesday, February 28th. The company reported $1.25 EPS for the quarter, topping the consensus estimate of ($0.59) by $1.84. The company had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. As a group, equities analysts expect that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. HC Wainwright assumed coverage on Voyager Therapeutics in a report on Tuesday, March 19th. They set a “buy” rating and a $30.00 target price on the stock. Citigroup assumed coverage on Voyager Therapeutics in a report on Thursday, March 7th. They set a “buy” rating and a $16.00 target price on the stock. Guggenheim began coverage on Voyager Therapeutics in a report on Tuesday, March 26th. They set a “buy” rating and a $22.00 target price on the stock. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. Finally, Wells Fargo & Company upgraded Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $9.00 to $14.00 in a research report on Tuesday, January 2nd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.33.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.